300122 Chongqing Zhifei Biological Products
- 34.56
- +0.10+0.29%
Chongqing Zhifei Biological Products News
Vaccine leaders have lost 280 billion
No more highlights
Chongqing Zhifei Biological Products Co., Ltd. Just Missed EPS By 35%: Here's What Analysts Think Will Happen Next
The analysts might have been a bit too bullish on Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122), given that the company fell short of expectations when it released its quarterly results
Benign Growth For Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122) Underpins Stock's 25% Plummet
The Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122) share price has fared very poorly over the last month, falling by a substantial 25%. Instead of being rewarded, shareholders who hav
Investors in Chongqing Zhifei Biological Products (SZSE:300122) Have Unfortunately Lost 62% Over the Last Three Years
If you love investing in stocks you're bound to buy some losers. Long term Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122) shareholders know that all too well, since the share price is d
Zhifei Biotech (300122.SZ): As of March 20, 2024, the number of common shareholders of the company was 93,392
Gelonghui, April 3 | Zhifei Biotech (300122.SZ) said on the investor interactive platform that as of March 20, 2024, the number of common shareholders of the company was 93,392.
Zhifei Biotech (300122.SZ): The repurchase was completed with a total cost of 300 million yuan to repurchase 6.2103 million shares
Gelonghui March 28 丨 Zhifei Biotech (300122.SZ) announced that as of the announcement disclosure date, the company's share repurchase had been completed. As of the disclosure date of this announcement, the company has repurchased a total of 62,02.53 million shares of the company's shares through a dedicated securities account, accounting for 0.26% of the company's current total share capital. The highest transaction price was 50.42 yuan/share, the lowest transaction price was 45.85 yuan/share, and the total transaction amount was RMB 300 million (excluding transaction fees).
Guoxin Securities: The pharmaceutical industry is entering an upward inflection point in the medium to long term, and focus on high growth targets in the quarterly report in the short term
The pharmaceutical industry currently has low growth, low profitability, undervaluation, and low transaction attention, and is entering a major layout range at an upward inflection point in the medium to long term.
Zhifei Biotech (300122.SZ): spent a total of 107 million yuan to buy back 2.15 million shares
Gelonghui March 18 丨 Zhifei Biotech (300122.SZ) announced that the company voluntarily disclosed the details of the company's share repurchase progress as of the disclosure date of this announcement. As of March 18, 2024, the company repurchased 2,151,800 shares of the company's shares through a dedicated securities account, accounting for 0.09% of the company's current total share capital. The highest transaction price was 50.34 yuan/share, the lowest transaction price was 49.28 yuan/share, and the total transaction amount was RMB 107,338,040.
With 59% Ownership, Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122) Insiders Have a Lot Riding on the Company's Future
Key Insights Significant insider control over Chongqing Zhifei Biological Products implies vested interests in company growth 54% of the business is held by the top 2 shareholders 17% of Chongqin
Guoxin Securities: Focus on the immediate needs of medical care, focus on the high growth targets of the first quarter report
The pharmaceutical industry currently has low growth, low profitability, undervaluation, and low transaction attention, and is entering a major layout range at an upward inflection point in the medium to long term.
Zhifei Biotech (300122.SZ): As of February 20, 2024, the number of common shareholders of the company was 79,778
Gelonghui March 8 | Zhifei Biotech (300122.SZ) said on the investor interactive platform that as of February 20, 2024, the number of common shareholders of the company was 79,778.
Zhifei Biotech (300122.SZ): Plans to spend 300 million yuan to 500 million yuan to buy back shares
Gelonghui, February 22丨Zhifei Biotech (300122.SZ) announced that the company plans to repurchase publicly issued RMB common shares (A shares); the repurchased shares will be used to cancel and reduce the company's registered capital; the total repurchase capital will not be less than RMB 300 million (including the number of shares) and no more than RMB 500 million (including the number of shares), and the repurchase price will not exceed RMB 75 yuan/share (including capital); the maximum repurchase price is RMB 75 per share (including capital)., the estimated number of shares that can be repurchased is 6.6667 million shares, approximately
Here's Why Chongqing Zhifei Biological Products (SZSE:300122) Can Manage Its Debt Responsibly
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
The Market Doesn't Like What It Sees From Chongqing Zhifei Biological Products Co., Ltd.'s (SZSE:300122) Earnings Yet As Shares Tumble 26%
The Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122) share price has fared very poorly over the last month, falling by a substantial 26%. The drop over the last 30 days has capped off a
Pacific Securities: The era of high growth in the shingles market begins, and the blue ocean of big single products is expected to gradually grow
The rapidly growing Blue Ocean market for shingles is expected, and the promotion system and reimbursement system need to be improved.
Declining Stock and Solid Fundamentals: Is The Market Wrong About Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122)?
Chongqing Zhifei Biological Products (SZSE:300122) has had a rough month with its share price down 15%. However, a closer look at its sound financials might cause you to think again. Given that fund
Open Source Securities: The RSV vaccine has broad prospects, and the domestic research pipeline can be expected in the future
Global RSV vaccines and antibodies are being marketed one after another, and domestic research pipelines can be expected in the future
An Intrinsic Calculation For Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122) Suggests It's 35% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, Chongqing Zhifei Biological Products fair value estimate is CN¥88.73 Chongqing Zhifei Biological Products' CN¥57.79 share price signals that
Here's Why We Think Chongqing Zhifei Biological Products (SZSE:300122) Might Deserve Your Attention Today
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage
Zhifei Biological Products to Acquire Local Biopharma Firm, Expanding Into Metabolic Disease Treatments
Chongqing Zhifei Biological Products (SHE:300122) has agreed to acquire a local biopharmaceutical company in a move that will enable it to enter the field of therapeutic biopharmaceuticals, specifical
Analysis
Price Target
No Data
